Research
Hormonal
Intensive blood pressure lowering to <130 mm Hg may be better tolerated and beneficial for perimenopausal women with diabetes compared to older populations, though standard guidelines recommend <140/90 mm Hg.
Discuss with your doctor if a lower blood pressure target (below 130 systolic) is appropriate for you, as younger women may tolerate it better than older patients, potentially offering more stroke protection.
GoodQualifiesMEDIUM confidence
Perimenopausal and newly postmenopausal women are younger than the overall population of persons with diabetes and hypertension. These younger women may be able to tolerate blood pressure reductions of <130 mm Hg better than older populations...
Why this rating
Based on meta-analyses and physiological reasoning.
Source
Management of Cardiovascular Risk in Perimenopausal Women with Diabetes
Catherine Kim · Diabetes & Metabolism Journal · 2021
DOI 10.4093/dmj.2020.0262
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Estrogen therapy does not reduce cardiovascular disease events and may increase stroke risk in postmenopausal women, particularly those with diabetes, and is not recommended for chronic disease prevention.Strong
- Lifestyle behaviors (smoking cessation, weight reduction, physical activity, sodium restriction) are the core management strategy for cardiovascular risk in women with diabetes, despite limited randomized trial evidence for mortality reduction.Good
- Specific hypoglycemic agents, SGLT-2 inhibitors and GLP-1 receptor agonists, reduce cardiovascular event risk in patients with diabetes, particularly those with a history of CVD, independent of glycemic control levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →